Ojer Pharma Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$3.19M
- Investors
-
9
Ojer Pharma General Information
Description
Operator of pharmaceutical products intended to offer therapeutic dermatological alternatives to patients. The company offers various dermatological medicines and products that meet the needs of patients internationally, enabling patients to avail themselves of bioadhesive products with competitive advantages.
Contact Information
Website
www.ojerpharma.comCorporate Office
- Sancho el Mayor 2, 1º Izda
- 31002 Pamplona
- Spain
Corporate Office
- Sancho el Mayor 2, 1º Izda
- 31002 Pamplona
- Spain
Ojer Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 19-Mar-2023 | $3.19M | Completed | Generating Revenue | ||
| 6. Later Stage VC | 01-Jul-2020 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series A) | 01-Oct-2019 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 17-Jul-2014 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 02-Jun-2011 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 29-Jun-2007 | $671K | $671K | Completed | Generating Revenue | |
| 1. University Spin-Out | 01-Jan-2005 | Completed | Generating Revenue |
Ojer Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 248,500 | $0.011253 | $2.26 | $2.26 | 1x | $2.26 | 15.8% | |
| Ordinary | 388,600 | $0.011253 | $1.25 | $1.25 | 1x | $1.25 | 24.7% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Ojer Pharma Patents
Ojer Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2013363788-A1 | Gel compositions | Active | 17-Dec-2012 | ||
| AU-2013363788-B2 | Gel compositions | Active | 17-Dec-2012 | ||
| CA-2893656-A1 | Gel compositions | Active | 17-Dec-2012 | ||
| CA-2893656-C | Gel compositions | Active | 17-Dec-2012 | ||
| EP-2742932-A1 | Gel compositions | Inactive | 17-Dec-2012 | A61K9/0014 |
Ojer Pharma Signals
Ojer Pharma Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Vegal Farmacéutica | Corporation | Minority | ||
| Easo Ventures | Venture Capital | Minority | ||
| Fundacion Cajanavarra | Limited Partner | Minority | ||
| University Foundation of Navarre | Other | Minority | ||
| Inveready Asset Management | Venture Capital | Minority |
Ojer Pharma FAQs
-
When was Ojer Pharma founded?
Ojer Pharma was founded in 2005.
-
Where is Ojer Pharma headquartered?
Ojer Pharma is headquartered in Pamplona, Spain.
-
What is the size of Ojer Pharma?
Ojer Pharma has 18 total employees.
-
What industry is Ojer Pharma in?
Ojer Pharma’s primary industry is Pharmaceuticals.
-
Is Ojer Pharma a private or public company?
Ojer Pharma is a Private company.
-
What is Ojer Pharma’s current revenue?
The current revenue for Ojer Pharma is .
-
How much funding has Ojer Pharma raised over time?
Ojer Pharma has raised $7.46M.
-
Who are Ojer Pharma’s investors?
Vegal Farmacéutica, Easo Ventures, Fundacion Cajanavarra, University Foundation of Navarre, and Inveready Asset Management are 5 of 9 investors who have invested in Ojer Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process